Cardiac Dimensions Raises $35 Million in Series D Financing
Summary
KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions\xae, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced it has closed a $35 million Series D financing round. This funding will enable us to continue providing Carillon therapy to a large population of patients in dire need of treatment, said Cardiac Dimensions CEO Rick Wypych. With strong reimbursement in place in key European markets, we also look forward to expanding adoption in these markets and adding new geographies this year.We have been impressed with Carillons ability to improve patients lives both in clinical studies and in real-world use, and with the companys ability to leverage these results to grow adoption and commercial sales, said Matt McNamara, Chief Investment Officer and Board Director for Horizon 3 Healthcare. The Carillon therapy is the only indirect, no-touch mitral valve repair option designed to produce an annuloplasty effect while initiating left ventricular remodeling and improving long-term survival for patients. It is considered an investigational device in the U.S. For more information, please visit www.CardiacDimensions.com.Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions.